Heplisav-B
Payments companies reported to CMS as associated with Heplisav-B. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Heplisav-B, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Heplisav-B
These are the largest totals companies reported as associated with Heplisav-B. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Teck Ling | Palo Alto, CA | Internal Medicine | $753,483.67 |
| Sean Bennett | Charlottesville, VA | $45,237.50 | |
| Arun Jesudian | New York, NY | Hepatology | $28,440.00 |
| Syeda Amna Husain | Marlboro, NJ | Pediatrics | $25,500.00 |
| Peter Patriarca | Bethesda, MD | $15,900.00 | |
| Kathryn Edwards | Nashville, TN | Pediatric Infectious Diseases | $13,484.01 |
| Walter Orenstein | Atlanta, GA | Infectious Disease | $5,600.00 |
| David Kim | Columbia, MD | Cardiovascular Disease | $5,400.00 |
| Kelly Moore | Nashville, TN | Public Health & General Preventive Medicine | $5,400.00 |
| Donald Middleton | Pittsburgh, PA | Internal Medicine | $3,680.00 |
Prescribed Heplisav-B?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.